Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. BeOne Medicines is joining the PD-1xVEGF race with an option for a trispecific ...

India’s AZB & Partners and White & Case are advising Sun Pharmaceutical Industries Limited on its agreement to acquire Organon & Co., while Sullivan & Cromwell and Cyril Amarchand Mangaldas (CAM) are ...

Indian generic medicines giant Sun Pharmaceutical Industries is buying the women’s health company Organon in a deal worth $11.75 billion. The deal grants Sun Pharma, India’s largest pharmaceutical ...

India’s Sun Pharmaceutical Industries 5247150.24%increase; green up pointing triangle has agreed to acquire U.S. drugmaker Organon OGN-0.15%decrease; red down pointing triangle in an $11.75 billion ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) of women’s health leader Organon. With its $11.75 billion buyout, Sun has ...

Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women’s health-care company Organon & Co., expanding its global reach with one of the biggest outbound deals by an Indian ...

Organon & Co. OGN said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion. According to the terms of the agreement, ...

Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion. Sun Pharmaceutical will buy all outstanding shares of ...

April 26 (Reuters) - Sun Pharmaceutical Industries (SUN.NS), opens new tab will buy U.S. drugmaker Organon & Co (OGN.N), opens new tab in an all-cash deal valued at about $11.75 billion including debt ...

A Sun Pharmaceutical Industries researcher at work. Sun Pharma has agreed to acquire Organon, the women’s health drug developer spun out of Merck & Co., for $11.75 billion in a deal intended to ...